NASDAQ:TCDA - Tricida Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started $29.87 +0.49 (+1.67 %) (As of 12/10/2018 04:41 AM ET)Previous Close$29.87Today's Range$28.00 - $30.0652-Week Range$21.87 - $40.10Volume92,272 shsAverage Volume78,514 shsMarket Capitalization$1.26 billionP/E RatioN/ADividend YieldN/ABetaN/A ProfileDiscussionAnalyst RatingsChartEarningsInsider TradesInstitutional OwnershipHeadlinesSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Tricida, Inc. operates as a pharmaceutical company. It focuses on the development and commercialization of TRC101, a non-absorbed orally-administered polymer drug that has completed Phase III clinical trials to treat metabolic acidosis in patients with chronic kidney disease. The company was founded in 2013 and is headquartered in South San Francisco, California. Receive TCDA News and Ratings via Email Sign-up to receive the latest news and ratings for TCDA and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:TCDA Previous Symbol CUSIPN/A Webwww.tricida.com Phone415-429-7800 Debt Debt-to-Equity Ratio0.11 Current Ratio12.68 Quick Ratio12.68 Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/A Profitability EPS (Most Recent Fiscal Year)N/A Net IncomeN/A Net MarginsN/A Return on EquityN/A Return on AssetsN/A Miscellaneous Employees61 Outstanding Shares42,110,000Market Cap$1.26 billion OptionableNot Optionable Tricida (NASDAQ:TCDA) Frequently Asked Questions What is Tricida's stock symbol? Tricida trades on the NASDAQ under the ticker symbol "TCDA." How were Tricida's earnings last quarter? Tricida Inc (NASDAQ:TCDA) posted its quarterly earnings data on Thursday, November, 8th. The company reported ($0.65) earnings per share (EPS) for the quarter, topping the Zacks' consensus estimate of ($0.84) by $0.19. View Tricida's Earnings History. When is Tricida's next earnings date? Tricida is scheduled to release their next quarterly earnings announcement on Thursday, February 14th 2019. View Earnings Estimates for Tricida. What price target have analysts set for TCDA? 3 equities research analysts have issued twelve-month price targets for Tricida's shares. Their forecasts range from $32.00 to $50.00. On average, they anticipate Tricida's share price to reach $38.6667 in the next twelve months. This suggests a possible upside of 29.4% from the stock's current price. View Analyst Price Targets for Tricida. What is the consensus analysts' recommendation for Tricida? 3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Tricida in the last year. There are currently 2 hold ratings and 1 buy rating for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Tricida. Has Tricida been receiving favorable news coverage? Media stories about TCDA stock have been trending positive on Monday, InfoTrie reports. The research group identifies negative and positive press coverage by analyzing more than six thousand blog and news sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores nearest to five being the most favorable. Tricida earned a news impact score of 2.1 on InfoTrie's scale. They also gave media headlines about the company a news buzz of 10.0 out of 10, meaning that recent press coverage is extremely likely to have an effect on the stock's share price in the immediate future. Who are some of Tricida's key competitors? Some companies that are related to Tricida include Amarin (AMRN), SAGE Therapeutics (SAGE), United Therapeutics (UTHR), HUTCHISON CHINA/S (HCM), Loxo Oncology (LOXO), TESARO (TSRO), Taro Pharmaceutical Industries (TARO), GW Pharmaceuticals PLC- (GWPH), Emergent Biosolutions (EBS), Horizon Pharma (HZNP), Array Biopharma (ARRY), FibroGen (FGEN), Ligand Pharmaceuticals (LGND), Agios Pharmaceuticals (AGIO) and Intercept Pharmaceuticals (ICPT). Who are Tricida's key executives? Tricida's management team includes the folowing people: Dr. Gerrit Klaerner, Founder, Pres, CEO & Exec. Director (Age 47)Mr. Geoffrey M. Parker, CFO & Sr. VP (Age 53)Dr. Wilhelm Stahl, Chief Technology Officer & Sr. VP (Age 58)Steffen Pietzke, VP of Fin. & Chief Accounting OfficerJackie Cossmon, VP of Investor Relations & Communications When did Tricida IPO? (TCDA) raised $175 million in an initial public offering on Thursday, June 28th 2018. The company issued 10,300,000 shares at $16.00-$18.00 per share. Goldman Sachs, J.P. Morgan and Cowen served as the underwriters for the IPO. When does Tricida's lock-up period expire? Tricida's lock-up period expires on Tuesday, December 25th. Tricida had issued 11,700,000 shares in its initial public offering on June 28th. The total size of the offering was $222,300,000 based on an initial share price of $19.00. After the end of Tricida's lock-up period, company insiders and major shareholders will be able to sell their shares of the company. Who are Tricida's major shareholders? Tricida's stock is owned by a number of of retail and institutional investors. Top institutional shareholders include FMR LLC (2.63%), Vanguard Group Inc. (2.59%), BlackRock Inc. (2.39%), JPMorgan Chase & Co. (1.63%), JPMorgan Chase & Co. (1.63%) and VHCP Management III LLC (1.55%). Company insiders that own Tricida stock include Beek Jeroen B Van, Edward J Hejlek, Geoffrey M Parker, Longitude Capital Partners Ii,, Sandra I Coufal and Steffen Pietzke. View Institutional Ownership Trends for Tricida. Which major investors are selling Tricida stock? TCDA stock was sold by a variety of institutional investors in the last quarter, including Laurion Capital Management LP, Marshall Wace North America L.P., FMR LLC and Redmile Group LLC. View Insider Buying and Selling for Tricida. Which major investors are buying Tricida stock? TCDA stock was bought by a variety of institutional investors in the last quarter, including Vanguard Group Inc., BlackRock Inc., VHCP Management III LLC, JPMorgan Chase & Co., JPMorgan Chase & Co., Opaleye Management Inc., Bank of New York Mellon Corp and TIAA CREF Investment Management LLC. Company insiders that have bought Tricida stock in the last two years include Beek Jeroen B Van, Edward J Hejlek, Geoffrey M Parker, Longitude Capital Partners Ii,, Sandra I Coufal and Steffen Pietzke. View Insider Buying and Selling for Tricida. How do I buy shares of Tricida? Shares of TCDA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is Tricida's stock price today? One share of TCDA stock can currently be purchased for approximately $29.87. How big of a company is Tricida? Tricida has a market capitalization of $1.26 billion. Tricida employs 61 workers across the globe. What is Tricida's official website? The official website for Tricida is http://www.tricida.com. How can I contact Tricida? Tricida's mailing address is 7000 SHORELINE COURT SUITE 201, SOUTH SAN FRANCISCO CA, 94080. The company can be reached via phone at 415-429-7800 or via email at [email protected] MarketBeat Community Rating for Tricida (NASDAQ TCDA)Community Ranking: 2.1 out of 5 ( )Outperform Votes: 31 (Vote Outperform)Underperform Votes: 42 (Vote Underperform)Total Votes: 73MarketBeat's community ratings are surveys of what our community members think about Tricida and other stocks. Vote "Outperform" if you believe TCDA will outperform the S&P 500 over the long term. Vote "Underperform" if you believe TCDA will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 12/10/2018 by MarketBeat.com StaffFeatured Article: Why do companies issue stock splits?